European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Nicholas C P Cross; Thomas Ernst; Susan Branford; Jean-Michel Cayuela; Michael Deininger; Alice Fabarius; Dennis Dong Hwan Kim; Katerina Machova Polakova; Jerald P Radich; Rüdiger Hehlmann; Andreas Hochhaus; Jane F Apperley; Simona Soverini

doi:10.1038/s41375-023-02048-y

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.

Authors

Affiliations

¹ Faculty of Medicine, University of Southampton, Southampton, UK. ncpc@soton.ac.uk.
² Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
³ Centre for Cancer Biology and SA Pathology, Adelaide, SA, Australia.
⁴ Laboratory of Hematology, University Hospital Saint-Louis, AP-HP and EA3518, Université Paris Cité, Paris, France.
⁵ Huntsman Cancer Center Salt Lake City, Salt Lake City, UT, USA.
⁶ III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.
⁷ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
⁸ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
⁹ Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹⁰ ELN Foundation, Weinheim, Germany.
¹¹ Centre for Haematology, Imperial College London, London, UK.
¹² Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK.
¹³ Department of Medical and Surgical Sciences, Institute of Hematology "Lorenzo e Ariosto Seràgnoli", University of Bologna, Bologna, Italy.

Abstract

From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons for resistance, relapse or progression. Our scientific and clinical knowledge underpinning these requirements continues to evolve, as do laboratory methods and technologies. The European LeukemiaNet convened an expert panel to critically consider the current status of genetic laboratory approaches to help diagnose and manage CML patients. Our recommendations focus on current best practice and highlight the strengths and pitfalls of commonly used laboratory tests.

Publication types

Review

MeSH terms

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy
Protein Kinase Inhibitors*
Recurrence

Substances

Protein Kinase Inhibitors